Intranasal administration of midazolam in a cyclodextrin based formulation: bioavailability and clinical evaluation in humans
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Your vote was cast
Thank you for your feedback
Thank you for your feedback
MetadataShow full item record
CitationPharmazie. 2001, 56(12):963-6
AbstractIntranasal administration of midazolam has been of particular interest because of the rapid and reliable onset of action, predictable effects, and avoidance of injections. The available intravenous formulation (Dormicum i.v. solution from Hoffmann-La Roche) is however less than optimal for intranasal administration due to low midazolam concentration and acidity of the formulation (pH 3.0-3.3). In this study midazolam was formulated in aqueous sulfobutylether-beta-cyclodextrin buffer solution. The nasal spray was tested in 12 healthy volunteers and compared to intravenous midazolam in an open crossover trial. Clinical sedation effects, irritation, and serum drug levels were monitored. The absolute bioavailability of midazolam in the nasal formulation was determined to be 64 +/- 19% (mean +/- standard deviation). The peak serum concentration from nasal application, 42 +/- 11 ng ml-1, was reached within 10-15 min following administration and clinical sedative effects were observed within 5 to 10 min and lasted for about 40 min. Intravenous administration gave clinical sedative effects within 3 to 4 min, which lasted for about 35 minutes. Mild to moderate, transient irritation of nasal and pharyngeal mucosa was reported. The nasal formulation approaches the intravenous form in speed of absorption, serum concentration and clinical sedation effect. No serious side effects were observed.
DescriptionTo access publisher full text version of this article. Please click on the hyperlink in Additional Links field
- Intranasal midazolam: a comparison of two delivery devices in human volunteers.
- Authors: Dale O, Nilsen T, Loftsson T, Hjorth Tønnesen H, Klepstad P, Kaasa S, Holand T, Djupesland PG
- Issue date: 2006 Oct
- [Intranasal and buccal midazolam in the treatment of acute seizures].
- Authors: Armijo JA, Herranz JL, Pena Pardo MA, Adín J
- Issue date: 2004 Mar 1-15
- A pharmacokinetic and pharmacodynamic study, in healthy volunteers, of a rapidly absorbed intranasal midazolam formulation.
- Authors: Wermeling DP, Record KA, Archer SM, Rudy AC
- Issue date: 2009 Feb
- Bioavailability of a novel midazolam gel after intranasal administration in dogs.
- Authors: Eagleson JS, Platt SR, Strong DL, Kent M, Freeman AC, Nghiem PP, Zheng B, White CA
- Issue date: 2012 Apr
- A pharmacokinetic study of midazolam in dogs: nasal drop vs. atomizer administration.
- Authors: Henry RJ, Ruano N, Casto D, Wolf RH
- Issue date: 1998 Sep-Oct